'김갑성' 기자의 전체기사
-
CANEUS & Government of Maharashtra Announce Partnership…
[ 메디채널 김갑성 기자 ] To Establish World's First Global Mid-TRL Innovation Acceleration and Skilling Institute for Aerospace, Space, Energy and Deep Technology DAVOS, Switzerland, Jan. 23, 2026 -- CANEUS International, in partnership with the Government of Maharashtra (India), today announced plans to establish the world's first dedicated Mid-TRL (Technology Readiness Level 4–6) Institute in Mumbai, Metropolitan Region (MMR) aligning with the World Economic Forum's 2026 theme of deploying innovation at scale, responsibly. The MoU was signed in the presence of Chief Minister
- 김갑성 기자
- 2026-01-23 21:43
-
Insilico Medicine Receives IND Approval from FDA for ISM8969, an…
[ 메디채널 김갑성 기자 ] Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles. ISM8969 is a novel oral therapeutic candidate developed through Insilico's Pharma.AI, with best-in-class potential, unique brain penetrant traits, and favorable druggability profiles demonstrated in preclinical studies. Insilico Medicine has entered into a co-development collaboration agreement with Hygtia Therapeutics, with bo
- 김갑성 기자
- 2026-01-23 21:30
-
Ozelle Brings AI-Powered, Scenario-Ready Diagnostics to WH…
DUBAI, UAE, Jan. 23, 2026 -- Ozelle, a global innovator in intelligent diagnostics, will showcase its next-generation solution at WHX Labs Dubai 2026 (Feb 10–13, Booth S1.D58). Under the theme "AI × CBM: The Next-Generation of Complete Blood Morphology," Ozelle will highlight how diagnostic testing can evolve beyond standalone analyzers toward intelligent, scenario-ready solutions designed to bridge the gap between lab-grade precision and real-world clinical environments. AI × CBM: See More. Diagnose Smarter. Ozelle's AI-powered Complete Blood Morph
- 김갑성 기자
- 2026-01-23 18:00
-
오젤, 두바이 WHX Labs 2026에서 AI 기반 시나리오 대응 진단 솔루션 공개
[ 메디채널 김갑성 기자 ] 두바이, 아랍에미리트 2026년 1월 23일 -- 지능형 진단 분야의 글로벌 혁신 기업 오젤(Ozelle)이 올해 열리는 두바이 WHX Labs 2026(2월 10일~13일, 부스 S1.D58)에서 자사의 차세대 솔루션을 선보인다. 'AI × CBM: 차세대 CBM(AI x CBM: The Next-Generation of Complete Blood Morphology)'이라는 주제로 오젤은 진단 검사가 독립형 분석기를 넘어 실험실 수준의 정밀도와 실제 임상 환경 간의 격차를 해소하도록 설계된 지능형 시나리오 대응 솔루션으로 진화할 수 있는 방안을 강조할 예정이다. AI × CBM: 더 많이 보고, 더 스마트하게 진단.(See More. Diagnose Smarter.) 오젤의 AI 기반 CBM(Complete Blood Morphology)은 고해상도 이미징과 실시간 알고리즘 분석을 결합하여 혈액학 진단을 재정의한다. 이 시스템은 기존 수치 데이터를 넘어 NST, NSG, ALY, RET 등 다중 분류 세포를 식별하여 단 한 방울의 혈액으로도 조기 검출과 더 나
- 김갑성 기자
- 2026-01-23 18:00
-
The American Chamber of Commerce in Singapore (AmChamS…
[ 메디채널 김갑성 기자 ] Nearly 100 AmChamSG Members and Staff Commemorate Martin Luther King, Jr. Day of Service (MLK Day) by Supporting Senior Heartlanders in Need SINGAPORE, Jan. 23, 2026 -- The American Chamber of Commerce in Singapore (AmChamSG) commemorated Martin Luther King, Jr. Day of Service (MLK Day) through outreach to 400 frail and vulnerable senior households in Sembawang. Nearly 100 AmChamSG members and staff conducted wellness checks and distributed mandarin oranges in partnership with Blossom Seeds, a non-profit organization that supports vulnerable senior hear
- 김갑성 기자
- 2026-01-23 17:15
-
Study demonstrates effectiveness and economic value of…
AUCKLAND, New Zealand, Jan. 23, 2026 -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in the Journal of Trauma and Injury. MASTRR is the largest ongoing prospective, multicenter observational study to collect patient data from the use of a bioscaffold in complex reconstruction. To date, over 450 patients have been enrolled. The study, titled "Vascularized Tissue Coverage of Trauma and Acute Care Surgery Defects with Ovine For
- 김갑성 기자
- 2026-01-23 03:13
-
Insilico Medicine Launches Science MMAI Gym to Transform…
[ 메디채널 김갑성 기자 ] New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any causal or frontier LLM Up to 10x performance gains on key drug discovery benchmarks compared to LLMs that miss the mark on ~75–95% of tasks Advances Insilico's vision of Pharmaceutical Superintelligence (PSI) CAMBRIDGE, Mass., Jan. 22, 2026 -- Insilico Medicine ("Insilico", HKEX: 3696), a leading global AI-driven biotech company with a clinical-stage pipeline, today announced the launch of Science MMAI Gym, a domain-specific training environment desig
- 김갑성 기자
- 2026-01-22 22:37
-
Mindray Unveils Three-Pillar Growth Strategy at 2026 J.P. Morgan…
SHENZHEN, China, Jan. 22, 2026 -- May Li, Board Secretary of Mindray Medical (300760.SZ), delivered a keynote speech at the 44th J.P. Morgan Healthcare Conference (JPM Conference) on January 15, 2026, outlining the company's strategic vision for the next decade centered on three core pillars: Globalization, Recurring Business Expansion, and Intelli-Digitalization. The speech also showcased significant progress in Mindray's Large Language Model (LLM) product family and innovative solutions that are redefining clinical excellence worldwide. Globalization: Deepening Localization t
- 김갑성 기자
- 2026-01-22 22:11
-
Mabwell Announces First-Patient Dosed in Clinical Trial of No…
SHANGHAI, Jan. 22, 2026 -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in a clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumors. The Phase I/II study (NCT07216560) represents the first-in-human (FIH) study of 7MW4911 in the United States. The study aims to evaluate the safety, pharmacokinetics and efficacy
- 김갑성 기자
- 2026-01-22 22:00
-
Jin Medical Announces the Official Commencement Date of C…
CHANGZHOU, China, Jan. 22, 2026 -- Jin Medical International Ltd. (NASDAQ: ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment in China, announced today that its wholly-owned subsidiary, Zhongjin Medical Equipment (Anhui) Co., Ltd., has made significant progress in the final construction of its manufacturing facility in Chuzhou, Anhui Province, China. The Company is projected to launch full capacity production by the end of April 2026. The Company completed regulatory filings wit
- 김갑성 기자
- 2026-01-22 21:57
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 5하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 6대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 7만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2026-01-24_SAT
- Inside the Computing Power Behind Spatial Filmmaking: Hugh Hou Goes Hands-On at GIGABYTE Suite During CES 2026 05:00
- 空間映像制作を支えるコンピューティングの内幕：Hugh Hou氏、CES 2026のGIGABYTE Suiteでハンズオン開催 05:00
- 기가바이트, CES 2026서 공간 영화 제작용 고성능 컴퓨팅 파워 직접 시연 05:00
- 엘비라 디앙가니 오세, 제2회 퍼블릭 아트 아부다비 비엔날레 예술감독으로 선임 00:30
- EQT to Launch USD 371 million Tender Offer for MAMEZO 00:05
- GlobalGPT Mobile App Is Now Live -- A Complete AI Workspace in Your Pocket 00:00
2026-01-23_FRI
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2026년 01월 24일 06시 40분